Program
AK120
A development code. Also written as “AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)”.
Its studies are mostly in Dermatitis, Atopic · Asthma, led by Akeso.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 72 open or running | phase 3since Apr 21, 2024 | Sep 9, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 9, 2021First study: phase 2 study in Dermatitis, AtopicFirst studyNCT05048056 · 79 enrolled · United States, Australia, New Zealand
- Dec 1, 2021Phase 2 study in AsthmaNCT05155020 · 1 enrolled · China
- Jun 2, 2023Phase 2 study in Dermatitis, AtopicNCT06035354 · 427 enrolled · China
- Oct 16, 2023Phase 2 study in Dermatitis, AtopicNCT06092762 · 180 enrolled · China
- Apr 21, 2024Phase 3 study in Dermatitis, AtopicNCT06383468 · 420 planned · China
- Nov 14, 2024Phase 2 study in Dermatitis, AtopicNCT06700499 · 450 enrolled · China
- Dec 25, 2024Phase 2 study in Dermatitis, AtopicNCT06756126 · 24 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06756126Dermatitis, Atopic · China | 2 | Not yet recruiting | Jun 30, 2025 | 24 |
| NCT06700499Dermatitis, Atopic · China | 2 | Completed | Jul 31, 2025 | 450 |
| NCT06383468Dermatitis, Atopic · China | 3 | Recruiting | Jan 30, 2025 | 420 |
| NCT06092762Dermatitis, Atopic · China | 2 | Completed | Nov 13, 2024 | 180 |
| NCT06035354Dermatitis, Atopic · China | 2 | Completed | Jun 21, 2024 | 427 |
| NCT05155020Asthma · China | 2 | Terminated | Aug 5, 2022 | 1 |
| NCT05048056Dermatitis, Atopic · United States, Australia, New Zealand | 2 | Terminated | May 17, 2023 | 79 |
How it is read
Names in the registry
- “AK120”, 16 entries
- “AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)”, 1 entry
Codes read as this program: AK120.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 6 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.